Outlook Therapeutics, Inc.
LYTENAVA
neovascular age-related macular degeneration
Date
TBD
Approval decision · Date TBD estimated
What's at stake
A final FDA approval decision on LYTENAVA for neovascular age-related macular degeneration is expected Date TBD.
Primary source
· SEC 8-K
verified 14h ago
“The Company expects to resubmit the BLA in June 2026 as a Class 1 resubmission.”